DexCom stock: buy or sell?

DXCM stock price: $173.55 -0.47% At close on August 23rd, 2019

Updated on:
August 23rd, 2019


After marking all time highs today, DexCom depreciated -0.47% to $173.55.

DexCom, Inc., a medical device company, together with its subsidiaries, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally.

Should I buy DexCom stock?

Make a decision about when to buy or sell stocks is one of the hardest parts of being a trader or investor. Trading strategies are meant for helping you in the decision process of what stocks to choose and when is the best time to buy them. There are thousands of trading strategies for you to choose, but at we prefer those that are simple but successful.

These 3 buy setups work for DexCom stock now:

Buy setupElegible
New all-time highYes
New 52 week highYes
Price crossing up 200d MANo
100d MA crossing up 200d MAYes

Is DexCom stock a buy?

Everyday, hundreds of stock ratings are posted by financial analysts to indicate a particular stock's attractiveness. At, we collected 15 ratings published for DXCM stock in the last month.

The general sentiment of these ratings is bullish for DXCM stock, with 11 positive ratings.
Is DXCM a good stock to buy?
DateAnalyst / BrokerPrevious ratingCurrent rating
2019-8-1UBS Groupn/aNeutral
2019-8-1Robert W. Bairdn/aOutperform
2019-8-1Raymond Jamesn/aOutperform
2019-8-1JPMorgan Chase & Co.n/aOverweight
2019-8-1Canaccord Genuityn/aBuy
2019-8-1BTIG Researchn/aHold
2019-8-1Bank of American/aBuy
2019-6-6Northland Securitiesn/aHold
2019-5-2Raymond JamesOutperformOutperform
2019-4-30UBS GroupNeutralNeutral
2019-2-22Canaccord Genuityn/aBuy
2019-2-22Canaccord Genuityn/aBuy
2019-1-9Piper Jaffray CompaniesAverageOverweight

DexCom stock analysis

Daily outlook

DexCom closed today at $173.55 after marking a new all time high ($176.59) even it couldn't close with gains and depreciated a lame -0.47%.

Even the red candle ($173.55, -0.47%), DexCom marked new all time high at $176.59. Since last August/21 when SMA100d and SMA200d crossed up, DXCM price gained $5.27 per share (3.13%). Since price and SMA200d lines crossed up on June, DXCM climbed $47.57 (37.76%).

DXCM stock chart (daily)

Weekly outlook

DexCom reached new all time highs again this week, setting highs to $176.59. Shares ended at $173.55 and rocketed 6.03% during the week. Late July DXCM plummed a hair-raising -6.63% in just one week. This week was the third green week in a row.

Since SMA20d and SMA40w crossed up last week, DXCM price climbed $18.11 per share (11.65%). Since mid June when DXCM stock price broke up the SMA40w line, it gained $47.57 (37.76%).

DXCM stock chart (weekly)

DexCom stock price history

DexCom IPO was on April 14th, 2005 at $12.08 per share1. Since then, DXCM stock surged a 1,336.70%, with a yearly average of 95.50%. If you had invested $1,000 in DexCom stock in 2005, it would worth $13,367.00 today.

1: Adjusted price after possible price splits or reverse-splits.

DexCom stock historical price chart

DXCM stock reached all-time highs today with a price of $176.59.

DexCom stock price target is $166.30

Nobody can reliably foresee how stock prices may evolve in the future. However, banks and other financial institutions analysts, with the help of lots of data and algorithms do their best to predict the stock prices movement. You should not follow the analysts' DXCM stock price predictions in the hope that they will be met as they may be wrong and not met. We found 14 price predictions for DexCom stock released in the last month:
DXCM stock price predictions
DateAnalyst / BrokerActionPrevious targetCurrent targetDiff
2019-8-1UBS GroupRaises Target$140.00$160.0014.3%
2019-8-1Robert W. BairdRaises Target$180.00$186.003.3%
2019-8-1Raymond JamesRaises Target$150.00$172.0014.7%
2019-8-1JPMorgan Chase & Co.Raises Target$170.00$190.0011.8%
2019-8-1Canaccord GenuityReiterates$160.00$185.0015.6%
2019-8-1Bank of AmericaRaises Target$162.00$185.0014.2%
2019-6-6Northland SecuritiesReiteratesn/a$125.00-
2019-5-2Raymond JamesLowers Target$160.00$150.00-6.3%
2019-4-30UBS GroupLowers Target$150.00$140.00-6.7%
2019-2-22CowenRaises Target$150.00$175.0016.7%
2019-2-22Canaccord GenuityReiterates$140.00$160.0014.3%
2019-2-22Canaccord GenuityRaises Target$140.00$160.0014.3%
2019-1-9Piper Jaffray CompaniesRaises Targetn/a$165.00-
(in average)$154.30$166.308.0%
Moving in a range from $190.00 and $125.00, the price prediction for DXCM stock is $166.30. In average, analysts' outlook on DXCM price forecast is positive, upgrading the forecast by a 8.00% from previous estimations.

Financials and fundamental analysis

Earnings date and Earnings per Share

On February, DexCom presented its financial report, posting an astounding climb for the Earnings per Share (EPS) ratio. Experts expected $0.16 per share, but DexCom posted $0.54.
DXCM earnings date and EPS evolution
QuarterReporting dateEstimated EPSActual EPSSurprise

Annual financial results

Compared to 2017, last anual turnover report draw a super good gain of 43.58% to $1,031.60 M dollars. On the other hand, its income margin (compared to sales) dropped to -12.32%, that is $-127.10 million.

DXCM annual Sales and Income evolution
2013$160 M-$-29.80 M-18.6%-
2014$259 M62.00%$-22.40 M-8.6%-24.83%
2015$402 M55.09%$-57.60 M-14.3%157.14%
2016$573 M42.61%$-65.60 M-11.4%13.89%
2017$719 M25.33%$-50.20 M-7.0%-23.48%
2018$1,032 M43.58%$-127.10 M-12.3%153.19%

Quarterly financial results

DexCom reported $338.00 M in sales for 2018-Q4, a 26.73% improvement compared to previous quarter. Reported quarter earnings marked $-179.70 million with a profit margin of -53.17%. Profit margin plummed a -70.64% compared to previous quarter when profit margin was 17.47%. When comparing sales to same quarter last year, DexCom sales marked an exceptional growth and rocketed a 52.94%. Looking back to recent quarterly results, DexCom posted 3 negative quarters in a row.
DXCM quarterly Sales and Income evolution
2017-Q2$171 M-$2.90 M1.7%-
2017-Q3$185 M8.21%$-2.00 M-1.1%-168.97%
2017-Q4$221 M19.72%$-9.40 M-4.3%370.00%
2018-Q1$184 M-16.56%$-24.20 M-13.1%157.45%
2018-Q2$243 M31.51%$30.20 M12.5%-224.79%
2018-Q3$267 M9.98%$46.60 M17.5%54.30%
2018-Q4$338 M26.73%$-179.70 M-53.2%-485.62%
2019-Q1$281 M-17.01%$-26.90 M-9.6%-85.03%

DexCom ownership

When you are planning to invest in a company, it's worth to have a look its ownership structure.

Management staff in all public traded companies that hold equity is required to report every transaction to the SEC. For DexCom, 1.14% of all outstanding shares are owned by its staff.

Bearish positions for DXCM stock account 0.00%, no big difference from last month.

The following table compares ownership indicators for other stocks related to DexCom:

Market cap$15.8 B$148.5 B$67.0 B$44.1 B$349.2 B
Total shares91.1 M1,760.0 M269.7 M208.1 M2,660.0 M
Float shares90.0 M1,750.0 M269.1 M206.6 M2,630.0 M
  - Institutional holdings (%)100.2%76.5%87.5%0.0%69.2%
  - Insider holdings (%)1.1%0.7%0.3%3.9%0.1%
Shares in short selling0.0%0.0%0.0%0.0%0.0%

DexCom summary

Friday, August 23rd, 2019
Day range$172.45 - $176.59
Previous close$174.37
Session gain-0.47%
Average true range$5.59
50d mov avg$152.73
100d mov avg$136.86
200d mov avg$135.78
Daily pattern
Weekly pattern

DexCom performance

To better understand DexCom performance you must compare its gains with other related stocks in same sector or industry. We compared DexCom against , Becton, Dickinson and, Edwards Lifesciences, , Medtronic, Quidel, Tandem Diabetes Care and West Pharmaceutical Services in the following table:
BDXBecton, Dickinson...5.92%0.09%-1.56%
EWEdwards Lifescien...25.19%22.91%49.61%
TNDMTandem Diabetes C...2.22%38.27%74.12%
WSTWest Pharmaceutic...23.40%37.79%23.34%

DexCom competitors

We picked a few stocks to conform a list of DexCom competitors to review if you are interested in investing in DXCM:

Latest DexCom stock news